Development And Validation Of A Simple Model For Detection Of Early Hepatocellular Carcinoma In A Liver Cirrhosis Cohort

被引:5
作者
Li, Tao [1 ]
Li, Hongguang [2 ]
Wang, Aihua [3 ]
Su, Xiaoyan [1 ]
Zhao, Jingfang [1 ]
Cui, Yi [1 ]
Liu, Jun [4 ]
Hu, Jinhua [1 ]
机构
[1] Shandong First Med Univ, Dept Gastroenterol, Shandong Prov Hosp, Jinan, Shandong, Peoples R China
[2] Shandong Univ, Shandong Prov Hosp, Dept Hepatobiliary Surg, Shandong First Med Univ, Jinan, Shandong, Peoples R China
[3] Linyi Peoples Hosp, Dept Gastroenterol, Linyi, Shandong, Peoples R China
[4] Shandong First Med Univ, Dept Liver Transplantat & Hepatobiliary Surg, Shandong Prov Hosp, Jing 5 Rd, Jinan, Shandong, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2019年 / 11卷
关键词
hepatocellular carcinoma; PIVKA-II; AFP; liver cirrhosis; GAMMA-CARBOXY PROTHROMBIN; CLINICAL-PRACTICE GUIDELINES; AUTOLOGOUS GROWTH-FACTOR; DIAGNOSIS; BIOMARKERS; MANAGEMENT;
D O I
10.2147/CMAR.S221050
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: We aimed to develop a simple model combining protein induced by vitamin K antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) to detect early hepatocellular carcinoma (HCC) in liver cirrhosis (LC) patients. Method: One hundred and sixty-nine newly diagnosed early HCC patients and 242 LC patients without HCC were enrolled in the current case-control study. All subjects were randomly divided into analysis group and validation group. Serum levels of PIVKA-II, AFP and other laboratory parameters were detected. Chi-squared test, t-test and logistic regression were employed in statistical analysis. Results: PIVKA-II level in early HCC was significantly higher than that in LC (90.97 mAU/mL vs 18.00 mAU/mL, P < 0.01), as well as AFP level (15.00 ng/mL vs 2.00 ng/mL, P < 0.01) in analysis groups. Multivariate analysis showed that PIVAK-II, AFP, gender, and age were independent risk factors for early HCC detection among LC patients. A logistic regression model and a simple model combining PIVKA and AFP were conducted to detect early HCC. The ROC curve showed that among analysis groups, the area under the ROC curve (AUROC) of the logistic regression model and the simple model were 0.96 (95% CI 0.94-0.98) and 0.94 (95% CI 0.92-0.97), respectively. At a cut-off value of 56.03 the sensitivity and specificity of the simple model were 81.1% and 91.4%, respectively. In the validation group, the sensitivity and specificity of the simple model was 82.4% and 94.2%, respectively. The two models are comparable statistically for early HCC detection, but the logistic regression requires complex calculation. Conclusion: The present study indicates that the simple model combining PIVKA-II and AFP has comparable diagnostic efficiency in contrast to the logistic model but is easy to use clinically. It might be helpful for early HCC detection among liver cirrhosis patients.
引用
收藏
页码:9379 / 9386
页数:8
相关论文
共 27 条
  • [1] Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005
    Altekruse, Sean F.
    McGlynn, Katherine A.
    Reichman, Marsha E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1485 - 1491
  • [2] Management of Hepatocellular Carcinoma: An Update
    Bruix, Jordi
    Sherman, Morris
    [J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
  • [3] Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma
    Chen, Hongda
    Zhang, Yue
    Li, Siwen
    Li, Ni
    Chen, Yuhan
    Zhang, Bei
    Qu, Chunfeng
    Ding, Huiguo
    Huang, Jian
    Dai, Min
    [J]. CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1947 - 1958
  • [4] Diagnosis and treatment of hepatocellular carcinoma
    El-Serag, Hashem B.
    Marrero, Jorge A.
    Rudolph, Lenhard
    Reddy, K. Rajender
    [J]. GASTROENTEROLOGY, 2008, 134 (06) : 1752 - 1763
  • [5] Des-γ-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migrations
    Fujikawa, Tatsuya
    Shiraha, Hidenori
    Ueda, Naoki
    Takaoka, Nobuyuki
    Nakanishi, Yutaka
    Matsuo, Noriyuki
    Tanaka, Shigetomi
    Nishina, Shin-ichi
    Suzuki, Mayumi
    Takaki, Akinobu
    Sakaguchi, Kohsaku
    Shiratori, Yasushi
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (12) : 8741 - 8748
  • [6] Fujikawa T, 2009, ACTA MED OKAYAMA, V63, P299
  • [7] Hepatocellular carcinoma: From diagnosis to treatment
    Grandhi, Miral Sadaria
    Kim, Amy K.
    Ronnekleiv-Kelly, Sean M.
    Kamel, Ihab R.
    Ghasebeh, Mounes A.
    Pawlik, Timothy M.
    [J]. SURGICAL ONCOLOGY-OXFORD, 2016, 25 (02): : 74 - 85
  • [8] AASLD guidelines for the treatment of hepatocellular carcinoma
    Heimbach, Julie K.
    Kulik, Laura M.
    Finn, Richard S.
    Sirlin, Claude B.
    Abecassis, Michael M.
    Roberts, Lewis R.
    Zhu, Andrew X.
    Murad, M. Hassan
    Marrero, Jorge A.
    [J]. HEPATOLOGY, 2018, 67 (01) : 358 - 380
  • [9] Validation of a novel model for the early detection of hepatocellular carcinoma
    Hemken, Philip M.
    Sokoll, Lori J.
    Yang, Xiaoqing
    Dai, Jianliang
    Elliott, Debra
    Gawel, Susan H.
    Lucht, Michael
    Feng, Ziding
    Marrero, Jorge A.
    Srivastava, Sudhir
    Chan, Daniel W.
    Davis, Gerard J.
    [J]. CLINICAL PROTEOMICS, 2019, 16 (1)
  • [10] JS']JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
    Kudo, Masatoshi
    Matsui, Osamu
    Izumi, Namiki
    Iijima, Hiroko
    Kadoya, Masumi
    Imai, Yasuharu
    Okusaka, Takuji
    Miyayama, Shiro
    Tsuchiya, Kaoru
    Ueshima, Kazuomi
    Hiraoka, Atsushi
    Ikeda, Masafumi
    Ogasawara, Sadahisa
    Yamashita, Tatsuya
    Minami, Tetsuya
    Yamakado, Koichiro
    [J]. LIVER CANCER, 2014, 3 (3-4) : 458 - 468